Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Invested Capital (2019 - 2025)

Historic Invested Capital for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $965.5 million.

  • Madrigal Pharmaceuticals' Invested Capital rose 796.69% to $965.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $965.5 million, marking a year-over-year increase of 796.69%. This contributed to the annual value of $872.0 million for FY2024, which is 6742.13% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Invested Capital of $965.5 million as of Q3 2025, which was up 796.69% from $814.4 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Invested Capital's 5-year high stood at $973.7 million during Q2 2024, with a 5-year trough of $78.5 million in Q3 2022.
  • For the 5-year period, Madrigal Pharmaceuticals' Invested Capital averaged around $479.5 million, with its median value being $267.1 million (2022).
  • In the last 5 years, Madrigal Pharmaceuticals' Invested Capital plummeted by 6656.65% in 2022 and then soared by 42252.38% in 2024.
  • Madrigal Pharmaceuticals' Invested Capital (Quarter) stood at $196.1 million in 2021, then soared by 36.18% to $267.1 million in 2022, then soared by 95.01% to $520.8 million in 2023, then skyrocketed by 67.42% to $872.0 million in 2024, then rose by 10.73% to $965.5 million in 2025.
  • Its last three reported values are $965.5 million in Q3 2025, $814.4 million for Q2 2025, and $828.6 million during Q1 2025.